GE HealthCare management check
GEHC · Health Care · Health Care Equipment · CEO Peter J Arduini
Filings as of
6 good · 0 to watch · 1 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2022 grew to $136, against $122 for the peer group the company picked itself.
- Flag
Does pay follow performance?
Pay moved against returnsOver 3 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.32 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good
What does the CEO cost owners?
0.9% of net income$18.6m of reported pay in fiscal 2025, against $2.2bn of net income.
- Good
Do they own the stock?
Insiders are buyingThe CEO holds 241,606 shares, directly or through trusts (unvested awards not counted): about 0.9 years of pay. 8 insiders bought $6.4m on the open market in the last six months, with their own money, near the lows.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 0.6% of revenue in the latest year.
- Good
Is leadership stable?
7 leadership filings in 3 years7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Good
Are the books clean?
No red flags on fileNo restatements, auditor changes or late filings since 2022.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 65 | 26 | |
| Pay for performance | 34 | 85 | |
| CEO cost | 55 | 44 | |
| Skin in the game | 53 | 46 | |
| Dilution | 50 | 68 | |
| Stable leadership | 90 | 70 | |
| Clean books | 100 | 100 |
Closest peers
Others in Health Care Equipment, by management score. GE HealthCare is 29th of 60 in its sector.
- 115ABTAbbott Laboratories75
- 149SYKStryker Corporation72
- 156ISRGIntuitive Surgical72
- 188IDXXIdexx Laboratories69
- 192BSXBoston Scientific69
- 246RVTYRevvity64
- 256GEHCGE HealthCare64
- 294RMDResMed62
- 321STESteris60
- 353BDXBecton Dickinson58
Pay versus performance
From the proxy statement filed March 19, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | — | $18.6m | $19.6m | $5.7m | $136 | $122 | $2.2bn |
| 2024 | — | $19.5m | $13.4m | $5.2m | $130 | $114 | $2.0bn |
| 2023 | — | $24.5m | $29.8m | $9.1m | $128 | $101 | $1.6bn |
| 2022 | — | $10.5m | $7.3m | $4.7m | — | — | $2.0bn |
The board says pay is tied most to Organic revenue growth*. Its other key measures: Adjusted EBIT*, Free cash flow*.
Insiders and the CEO's stake
Peter J Arduini (President and CEO) held 241,606 shares directly after their latest Form 4 on Sep 3, 2026, roughly $17.0m at that filing's price.
8 insiders bought $6.4m on the open market in the last six months, with their own money, near the lows.
- BoughtH Lawrence Jr CulpDirector$5.0mMay 6, 2026
- BoughtKevin LoboDirector$642kMay 22, 2026
- BoughtPeter J ArduiniPresident and CEO$250kApr 30, 2026
- BoughtJames SaccaroChief Financial Officer$201kMay 1, 2026
Leadership and governance on file
- Sep 22, 2026Leadership change8-K 5.02
- Aug 18, 2026Leadership change8-K 5.02
- Jul 23, 2026Leadership change8-K 5.02
- Mar 17, 2026Leadership change8-K 5.02
- Jul 24, 2025Leadership change8-K 5.02
- Apr 15, 2024Leadership change8-K 5.02
- Feb 5, 2024Leadership change8-K 5.02
- May 9, 2023Leadership change8-K 5.02
- Mar 24, 2023Leadership change8-K 5.02
- Mar 3, 2023Leadership change8-K 5.02
- Feb 3, 2023Leadership change8-K 5.02
- Jan 4, 2023Leadership change8-K 5.02
Latest shareholder vote results: May 11, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $360.0m returned to owners in buybacks and dividends, 4% of net income, and $512.0m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.6bn | $18.3bn | $19.6bn | $19.7bn | $20.6bn |
| Net income | $2.2bn | $1.9bn | $1.6bn | $2.0bn | $2.1bn |
| Stock-based pay | $76.0m | $67.0m | $114.0m | $125.0m | $130.0m |
| Buybacks | — | — | $0 | $0 | $200.0m |
| Dividends | $0 | $0 | $41.0m | $55.0m | $64.0m |
| Diluted shares | 454m | 454m | 458m | 459m | 458m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.